Acarix publish EU growth prospectus in connection with rights issue of up to approximately SEK 51.8 million

The board of directors of Acarix AB ("Acarix" or the "Company") resolved on 25 September 2019, pursuant to the authorization granted by the extra general meeting on 16 August 2019, to carry out a new share issue of a maximum of 34,541,064 shares with preferential rights for the Company's existing shareholders at a subscription price of SEK 1.50, which may provide the Company with approximately SEK 51.8 million before deduction of transaction costs (the "Rights Issue"). The board of directors in Acarix has is connection therewith prepared an EU growth prospectus which today has been approved and registered by the Swedish Financial Supervisory Authority.

Acarix AB Press release publication of prospectus >>

Acarix AB Pressmeddelande offentliggörande av prospekt >>

About Acarix
Acarix was establish in 2009 and is listed on Nasdaq First North Growth Market. Acarix's CADScor@System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-on system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen.